|MDACC Study No:||GOG 0268 (clinicaltrials.gov NCT No: NCT01196429)|
|Title:||A Phase II Evaluation of Temsirolimus (CCI-779) (NCI Supplied Agent: 683864, IND #61010) in Combination with Carboplatin and Paclitaxel followed by Temsirolimus (CCI-779) Consolidation as First-line Therapy in the Treatment of Stage III-IV Clear Cell Carcinoma of the Ovary |
|Principal Investigator:||Jubilee Brown|
|Treatment Agent:||Carboplatin; Paclitaxel; Temsirolimus|
|Study Description:||The goal of this clinical research study is to learn if the combination of |
paclitaxel, carboplatin, and temsirolimus can help to control Stage III or
Stage IV clear cell cancer of the ovary in patients in the U.S. versus patients
in Japan. The safety of this study drug combination will also be studied.
If you are alcohol intolerant, docetaxel will be given instead of paclitaxel.